#nsclcs - Twitter Hashtag

9 months ago

🌟Cancer-Associated Fibroblasts (#CAFs) actively drive resistance to ALK inhibitors in #NSCLCs 💡#Alectinib + #Capmatinib and/or #Cilengitide showed better outcome than single agent in suppressing tumor growth in vivo. We offer for research use only.

MedChemExpress's tweet photo. 🌟Cancer-Associated Fibroblasts (#CAFs) actively drive resistance to ALK inhibitors in #NSCLCs

💡#Alectinib + #Capmatinib and/or #Cilengitide showed better outcome than single agent in suppressing tumor growth in vivo.

We offer for research use only. https://t.co/so43p38c29

0

1

0

90

MedChemExpress-US

@MCE_US

9 months ago

🔥Hot Off the Press | #CAFs actively drive resistance to ALK inhibitors in #NSCLCs 💡#Alectinib + #Capmatinib and/or #Cilengitide showed better outcome than single agent in suppressing tumor growth in vivo 🌟We provide alectinib, capmatinib and cilengitide for research use

MCE_US's tweet photo. 🔥Hot Off the Press | #CAFs actively drive resistance to ALK inhibitors in #NSCLCs
💡#Alectinib + #Capmatinib and/or #Cilengitide showed better outcome than single agent in suppressing tumor growth in vivo
🌟We provide alectinib, capmatinib and cilengitide for research use https://t.co/8Qp4BTZz2U

0

1

0

39

giovanni farinea @FarineaGiovanni

12 months ago

Proud to present my poster on #osimertinib efficacy in advanced #NSCLCs harbouring uncommon #EGFR mutations: analysis form Italian biomarker #ATLAS database 🇮🇹 🎯. @myESMO #esmo2025 @pbyronz @PassigliaFra #silvianovello

FarineaGiovanni's tweet photo. Proud to present my poster on #osimertinib efficacy in advanced #NSCLCs harbouring uncommon #EGFR mutations: analysis form Italian biomarker #ATLAS database 🇮🇹 🎯. @myESMO #esmo2025 @pbyronz @PassigliaFra #silvianovello https://t.co/p3Sp53vpdY

0

8

2

0

267

JTO & JTO CRR

@JTOonline

over 3 years ago

Nearly 1-2% of #NSCLCs harbor RET fusions. In order to provide characterization & outcome of this rare population, these authors found that patients w/RET+ NSCLC have mainly thoracic & bone disease & potentially improved survival w/specific RET inhibitors. https://t.co/iAACMRMmzS

JTOonline's tweet photo. Nearly 1-2% of #NSCLCs harbor RET fusions. In order to provide characterization & outcome of this rare population, these authors found that patients w/RET+ NSCLC have mainly thoracic & bone disease & potentially improved survival w/specific RET inhibitors. https://t.co/iAACMRMmzS https://t.co/lJoNhsXClQ

1

19

4

5

3K

Pulmonary Cell News

@pulmonary_news

almost 4 years ago

As a tumor suppressor with aberrant expression in ∼10% of #NSCLCs, SMARCA4 possesses many biological functions. Check out 'SMARCA4: Current Status and Future Perspectives in NSCLC' on innovative treatment 💉 strategies by SMARCA4 alterations! 🔗 https://t.co/1dwBEtszJw

pulmonary_news's tweet photo. As a tumor suppressor with aberrant expression in ∼10% of #NSCLCs, SMARCA4 possesses many biological functions.

Check out 'SMARCA4: Current Status and Future Perspectives in NSCLC' on innovative treatment 💉 strategies by SMARCA4 alterations!

🔗 https://t.co/1dwBEtszJw https://t.co/MO4slqrk0D

0

1

0

@onc_ce

about 4 years ago

4) #HER2 mutations were identified in 2006 as oncogenic drivers and are detected in 2-3% of #NSCLCs, more often in ♀️ pts, never-smokers and lung #adenocarcinoma #ADK. HER2 amp & HER2 mutations are distinct molecular targets in 🫁 cancers. See 🔓 https://t.co/ybJvIQ8scv

1

5

1

0

4baseCare @4baseCare

almost 5 years ago

#Immunotherapy has shown a remarkable contribution to the treatment of #NSCLCs. But data shows that NSCLCs affected individuals with #RET alteration have lesser PD-L1 and #TMB and are unresponsive towards #ICI drugs. Read more here:https://t.co/hghE4Wtq3I #MedTwitter #Genomics

4baseCare's tweet photo. #Immunotherapy has shown a remarkable contribution to the treatment of #NSCLCs.

But data shows that NSCLCs affected individuals with #RET alteration have lesser PD-L1 and #TMB and are unresponsive towards #ICI drugs.

Read more here:https://t.co/hghE4Wtq3I

#MedTwitter #Genomics https://t.co/HKLWzHrL1J

0

4

2

0

Carmelo Tuscano🇮🇹🇪🇺 @CTuscanoMD

almost 5 years ago

These pictures are taken from the @imrtlee book of contouring. These are the instructions for contouring post-op N2 #NSCLCs on regard the #LUNGART trial…as you can see volumes don’t follow the concept of ISRT drawing just pathologically involved levels….#radonc 2/2

1

3

0

1

0

Bill Cance @BillCance

about 5 years ago

Wonderful news made possible by many great minds-including early work from @ACS_Research Professors Drs. Matthew Meyerson @meyersonlab and Pasi Janne @DanaFarber who 1st showed #NSCLCs with #EGFR exon 20 insertions required alternative treatment strategies https://t.co/u1SdTxQSHJ

0

9

6

0

Sanjay Popat @DrSanjayPopat

about 5 years ago

@OncoloJo @dplanchard It’s amazing how many non-V600 BRAF driven #NSCLCs you find. #HuntTheDriver

1

2

0

Cancer Stem Cell News

@cancerscnews

over 5 years ago

🫁 Drs. Liancheng Lin and Shouguo Li identified a novel MCF2L‐AS1/miR‐873‐5p regulatory axis responsible for the #CSC‐like traits of #NSCLCs. https://t.co/S58m5L30H8

cancerscnews's tweet photo. 🫁 Drs. Liancheng Lin and Shouguo Li identified a novel MCF2L‐AS1/miR‐873‐5p regulatory axis responsible for the #CSC‐like traits of #NSCLCs.
https://t.co/S58m5L30H8 https://t.co/ABXn4lchYR

1

2

1

0

MedPage Oncology @MedpageOnco

over 7 years ago

"There is a growing appreciation that #EGFR-mutant #NSCLCs can undergo #SCLC transformation." @ASCO #lungcancer #NSCLC https://t.co/2NVXMy0HYK

0

7

0

Top Tweets for #nsclcs

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users